Advertisement
New Zealand markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6018
    -0.0016 (-0.27%)
     
  • NZD/EUR

    0.5585
    -0.0009 (-0.16%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    78.99
    -0.27 (-0.34%)
     
  • GOLD

    2,371.00
    +30.70 (+1.31%)
     
  • NASDAQ

    18,124.59
    +11.13 (+0.06%)
     
  • FTSE

    8,433.76
    +52.41 (+0.62%)
     
  • Dow Jones

    39,435.72
    +47.96 (+0.12%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7590
    -0.0090 (-0.01%)
     

Company News For Oct 12, 2018

Smart Beta ETF report for FGD
  • Delta Air Lines, Inc.’s DAL shares gained 3.6% after reporting third-quarter fiscal 2018 earnings of $1.80 per share, surpassing the Zacks Consensus Estimate of $1.74 per share

  • Shares of Walgreens Boots Alliance, Inc. WBA declined 2% after it reported fourth-quarter fiscal 2018 revenues of $131.53 billion, missing the Zacks Consensus Estimate of $131.60 billion

  • Costco Wholesale Corporation’s COST shares increased 0.4% after the company reported net sales of $13.6 billion in September, up 10.3% year-over-year

  • Shares of CRISPR Therapeutics AG CRSP advanced 0.9% after the company announced that a clinical hold on an application for a sickle cell disease treatment developed by Crispr and partner Vertex Pharmaceuticals had been lifted by the Food and Drug Association


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Delta Air Lines, Inc. (DAL) : Free Stock Analysis Report
 
Costco Wholesale Corporation (COST) : Free Stock Analysis Report
 
Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
 
CRISPR THERAPTC (CRSP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research